Phoenix PharmaLabs, Inc.

12 articles with Phoenix PharmaLabs, Inc.

• Phoenix PharmaLabs Successfully Completes Second Oversubscribed Netcapital Offering Raising more than $1 million to Fund Continued Development of Company’s Two Non-Addictive Opioid Compounds for Acute and Chronic Pain

  6/23/2021

  Phoenix PharmaLabs, Inc. today announced it has completed a second successful round of financing raising $1.07 million via the Netcapital ( https://netcapital.com ) equity funding portal.

• Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with the Acquisition of a Portfolio of NOP/Mu Agonist Compounds

  1/5/2021

  Phoenix PharmaLabs, a privately-held pre-clinical drug discovery company dedicated to the development of potent, non-addictive treatments for pain and addiction, today announced it has completed a license agreement with the University of Bath in England for exclusive rights to a portfolio of 25 NOP (Nociceptin) compounds. The specific terms of the license agreement were not disclosed. One of the compounds, formerly kn

• Phoenix PharmaLabs Announces New Investment Offering with Netcapital

  12/21/2020

  Phoenix PharmaLabs, a privately held, preclinical drug company dedicated to developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform: https://netcapital.com/companies/phoenix .

• Phoenix PharmaLabs Raises More Than $1.1 Million via Netcapital

  4/8/2019

  Funds to accelerate development of first non-addictive opioid

• Phoenix PharmaLabs: How Would Physicians Spend One Billion Dollars to Combat Opioid Crisis?

  3/5/2019

  85% Surveyed Said First Priority Is to Fund Research into Non-Addictive Pain Killers

• Phoenix PharmaLabs Announces Investment Offering to Support Additional Research of Non-Addictive Opioid

  10/15/2018

  Phoenix PharmaLabs today announced the launch of an equity offering campaign on the Netcapital platform.

• Phoenix PharmaLabs Awarded $2.7 Million Research Grant from DOD/USAMRAA for Further Development of Non-Addictive Opioid

  9/25/2018

  Phoenix PharmaLabs has been awarded a $2.7 million grant from the Department of Defense/US Army Medical Research Acquisition Activity.

• Phoenix PharmaLabs Awarded NIH/NIDA Grant to Study Non-Addictive Opioid PPL-103 for Potential use as Cocaine Addiction Therapy Drug

  9/5/2018

  This research is supported under award number R41DA044894.

• Phoenix PharmaLabs Co-Founder to speak at Upcoming College on Problems of Drug Dependence (CPDD) 80th Annual Meeting in San Diego

  5/24/2018

  Lawrence Toll, Ph.D., expected to describe company’s novel opioid that shows no signs of addiction potential

• Phoenix PharmaLabs, Inc. Releases New Data Confirming That Their Novel Opioid Shows No Signs Of Addiction Potential

  1/6/2016

• Novel Painkiller With Little Or No Signs Of Addiction And Other Serious Opioid Side Effects Patented By Phoenix PharmaLabs, Inc.

  4/8/2015

• Aoxing Pharmaceutical Company Inc. and Phoenix PharmaLabs, Inc. Announce Strategic Alliance to Co-Develop a Novel Class of Molecules in Pain and Drug Addiction Therapeutics

  6/3/2010